Loading briefing details...
News Brief
By: PointLine Media Research & Editorial Team
Category:Business,Health,Industry,Science & Environment
August 14, 2026
This milestone highlights the critical role of integrated research networks in accelerating drug development. By bridging the gap between sponsors and diverse patient populations, DM Clinical Research demonstrates how scaling high-quality, patient-centered infrastructure is essential for bringing life-saving medical innovations to market more efficiently and equitably.
DM Clinical Research is proud to celebrate twenty years of excellence in clinical trial management. Since its founding in 2006, the organization has evolved into a premier integrated network, dedicated to bridging the gap between innovative pharmaceutical developments and patient access. By maintaining a steadfast focus on patient-centric care, the company has successfully enrolled over 35,000 participants across 32 distinct therapeutic areas.
The organization’s growth is anchored by a robust network of more than 35 research sites, providing access to a patient population of nearly two million. CEO Mohammad Millwala attributes this success to a deep-rooted commitment to team collaboration and operational integrity. Recognized with prestigious industry honors like the SCRS Site Spark Award, the company continues to prioritize quality, speed, and diversity in every clinical trial it facilitates.
Looking toward the future, DM Clinical Research is committed to further expanding its footprint in underserved communities. By integrating cutting-edge technology with established physician partnerships, the company aims to accelerate the development of life-changing therapies. This milestone marks the beginning of a new chapter focused on scaling impact and ensuring that global medical advancements remain accessible to all patients in need.